Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Development Runs Completed

Author's Avatar
Nov 18, 2022

LONDON, UK / ACCESSWIRE / November 18, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO, Financial), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second and final Process Development ("PD") run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean rooms.